EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Secondary Genetic Events and Their Relationship to TP53 Mutation in Mantle Cell Lymphoma: A Sub-Study from the FIL_MANTLE-FIRST BIO on Behalf of Fondazione Italiana Linfomi (FIL)

Maria Elena Carazzolo iD, Francesca Maria Quaglia iD, Antonino Aparo iD, Alessia Moioli iD, Alice Parisi, Riccardo Moia, Francesco Piazza iD, Alessandro Re iD, Maria Chiara Tisi, Luca Nassi, Pietro Bulian, Alessia Castellino iD und 16 weitere

Cancers · 17.12.2025 · 17 (24) · 4027

DOI: 10.3390/cancers17244027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 17.12.2025. Verfasst von Maria Elena Carazzolo und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Verona, 37134 Verona, Italy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione Italiana Linfomi (FIL), Fondazione Giulia Maramotti, Fondazione GRADE and Leu-kemia and Lymphoma Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mantle Cell Lymphoma (MCL) is an aggressive malignancy with variable clinical behavior, largely reflecting the underlying molecular heterogeneity. The genomic landscape of MCL encompasses gene mutations with strong prognostic implications and secondary genetic events, which are also implicated in the pathogenesis and prognosis of the disease.

Methods

We evaluated the diagnostic samples of 73 patients with relapsed/refractory MCL that were enrolled in the Fondazione Italiana Linfomi Mantle First-BIO study. All patients had available data for correlating CNVs with the presence of TP53 mutation. Time to first relapse or progression of disease (POD) was used as the primary outcome measure.

Results

We identified CNVs associated with MCL, with Del 9p21.3 (CDKN2A) being the strongest predictor of shorter time to POD (p = 0.01), independently of TP53 mutation in multivariable analysis. Unsupervised clustering identified molecularly defined clusters that were associated with significantly different times to POD (p = 0.01). Pairwise log-rank tests confirmed TP53 mutated vs. wild-type (WT) as the strongest prognostic factor, with cluster assessment improving the prognostic predictivity among patients: clusters TP53-mut vs. TP53-WT, p = 0.001, HR = 3.92; and p = 0.014, HR = 2.23, respectively. In conclusion, CNV-based molecular clusters might represent a novel approach to identify patients at higher risk of treatment failure, further contributing to the prognostic predictivity of TP53 mutation.

Schlagwörter

Stichwörter der Autor:innen

CNVDel 9p21.3 (CDKN2A)MCLNGSPOD24TP53mantle cell lymphomaprognosis

Autor:innen und Institutionen

  • Department of Medicine, University of Verona, 37134 Verona, Italy.
  • Research Center LURM (Interdepartmental Laboratory of Medical Research), University of Verona, 37134 Verona, Italy.
  • UOC di Ematologia, DAI Medico Generale, AOUI Verona, 37134 Verona, Italy.
  • Department of Pathology and Diagnostics, University Hospital of Verona, 37126 Verona, Italy.
  • Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale and AOU Maggiore della Carità di Novara, 28100 Novara, Italy.
  • Department of Medicine, University of Padova and Unit of Hematology, Azienda Ospedale Università Padova, 35128 Padova, Italy.

ORCID-Profile: Maria Elena Carazzolo, Francesca Maria Quaglia, Antonino Aparo, Alessia Moioli, Francesco Piazza, Alessandro Re, Alessia Castellino, Vittorio Ruggero Zilioli, Piero Maria Stefani, Elisa Lucchini, Annalisa Arcari, Maurilio Ponzoni, Simone Ragaini, Jacopo Olivieri, Vittoria Salaorni, Simona Gambino, Carlo Visco

Förderung

  • Fondazione Italiana Linfomi (FIL), Fondazione Giulia Maramotti, Fondazione GRADE and Leu-kemia and Lymphoma Society

Zitieren

APA

Carazzolo, M. E., Quaglia, F. M., Aparo, A., Moioli, A., Parisi, A., Moia, R., Piazza, F., Re, A., Tisi, M. C., Nassi, L., Bulian, P., Castellino, A., Zilioli, V. R., Stefani, P. M., Fabbri, A., Lucchini, E., Arcari, A., Lorenzi, L., Famengo, B., …, & Visco, C. (2025). Secondary Genetic Events and Their Relationship to TP53 Mutation in Mantle Cell Lymphoma: A Sub-Study from the FIL_MANTLE-FIRST BIO on Behalf of Fondazione Italiana Linfomi (FIL). Cancers, 17(24), 4027. https://doi.org/10.3390/cancers17244027

Vancouver

Carazzolo ME, Quaglia FM, Aparo A, Moioli A, Parisi A, Moia R, et al. Secondary Genetic Events and Their Relationship to TP53 Mutation in Mantle Cell Lymphoma: A Sub-Study from the FIL_MANTLE-FIRST BIO on Behalf of Fondazione Italiana Linfomi (FIL). Cancers. 2025;17(24):4027. doi:10.3390/cancers17244027

BibTeX
@article{Carazzolo2025,
  author = {Carazzolo, Maria Elena and Quaglia, Francesca Maria and Aparo, Antonino and Moioli, Alessia and Parisi, Alice and Moia, Riccardo and Piazza, Francesco and Re, Alessandro and Tisi, Maria Chiara and Nassi, Luca and Bulian, Pietro and Castellino, Alessia and Zilioli, Vittorio Ruggero and Stefani, Piero Maria and Fabbri, Alberto and Lucchini, Elisa and Arcari, Annalisa and Lorenzi, Luisa and Famengo, Barbara and Ponzoni, Maurilio and Ferrari, Angela and Ragaini, Simone and Olivieri, Jacopo and Salaorni, Vittoria and Gambino, Simona and Galasso, Marilisa and Scupoli, Maria Teresa and Visco, Carlo},
  title = {Secondary Genetic Events and Their Relationship to TP53 Mutation in Mantle Cell Lymphoma: A Sub-Study from the FIL_MANTLE-FIRST BIO on Behalf of Fondazione Italiana Linfomi (FIL)},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {24},
  pages = {4027},
  doi = {10.3390/cancers17244027}
}
Kostenlos starten →